Health Catalyst, Inc.

NasdaqGS:HCAT Stock Report

Market Cap: US$435.7m

Health Catalyst Valuation

Is HCAT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HCAT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HCAT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HCAT's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for HCAT?

Other financial metrics that can be useful for relative valuation.

HCAT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA-6.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does HCAT's PS Ratio compare to its peers?

The above table shows the PS ratio for HCAT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.4x
SHCR Sharecare
0.6x7.9%US$295.7m
LFMD LifeMD
2.7x22.9%US$410.9m
MPLN MultiPlan
0.6x6.3%US$553.3m
SOPH SOPHiA GENETICS
5.5x21.8%US$343.5m
HCAT Health Catalyst
1.5x8.3%US$435.7m

Price-To-Sales vs Peers: HCAT is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (2.4x).


Price to Earnings Ratio vs Industry

How does HCAT's PE Ratio compare vs other companies in the US Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a26.0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a26.0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: HCAT is good value based on its Price-To-Sales Ratio (1.5x) compared to the US Healthcare Services industry average (1.9x).


Price to Sales Ratio vs Fair Ratio

What is HCAT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HCAT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio1.1x

Price-To-Sales vs Fair Ratio: HCAT is expensive based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HCAT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.44
US$11.93
+60.4%
20.9%US$16.00US$8.00n/a15
Mar ’25US$8.06
US$11.93
+48.1%
20.9%US$16.00US$8.00n/a15
Feb ’25US$9.88
US$12.40
+25.5%
20.6%US$17.00US$8.00n/a15
Jan ’25US$9.26
US$11.54
+24.6%
20.6%US$16.00US$8.00n/a13
Dec ’24US$7.61
US$11.69
+53.6%
21.1%US$16.00US$8.00n/a13
Nov ’24US$7.23
US$13.46
+86.2%
17.4%US$16.00US$8.00n/a13
Oct ’24US$10.12
US$14.92
+47.5%
13.0%US$20.00US$12.00n/a13
Sep ’24US$11.72
US$15.07
+28.6%
12.9%US$20.00US$12.00n/a14
Aug ’24US$14.32
US$15.00
+4.7%
14.7%US$20.00US$11.00n/a14
Jul ’24US$12.50
US$15.00
+20.0%
14.6%US$20.00US$11.00n/a13
Jun ’24US$11.27
US$15.00
+33.1%
14.6%US$20.00US$11.00n/a13
May ’24US$12.98
US$15.80
+21.7%
10.9%US$20.00US$13.00n/a15
Apr ’24US$11.67
US$15.85
+35.8%
11.3%US$20.00US$13.00n/a13
Mar ’24US$14.32
US$15.77
+10.1%
13.0%US$20.00US$11.00US$8.0613
Feb ’24US$13.82
US$13.46
-2.6%
22.5%US$17.00US$8.00US$9.8813
Jan ’24US$10.63
US$13.47
+26.7%
22.2%US$17.00US$8.00US$9.2615
Dec ’23US$10.64
US$13.47
+26.6%
22.2%US$17.00US$8.00US$7.6115
Nov ’23US$9.04
US$15.93
+76.3%
23.4%US$21.00US$9.00US$7.2315
Oct ’23US$9.70
US$17.43
+79.7%
15.9%US$21.00US$11.00US$10.1214
Sep ’23US$11.78
US$19.43
+64.9%
16.2%US$27.00US$15.00US$11.7214
Aug ’23US$16.99
US$24.64
+45.0%
22.7%US$35.00US$18.00US$14.3214
Jul ’23US$15.40
US$25.79
+67.4%
27.2%US$37.00US$17.00US$12.5014
Jun ’23US$14.03
US$25.79
+83.8%
27.2%US$37.00US$17.00US$11.2714
May ’23US$16.64
US$40.43
+143.0%
21.4%US$60.00US$28.00US$12.9814
Apr ’23US$27.63
US$41.62
+50.6%
19.6%US$60.00US$28.00US$11.6713
Mar ’23US$26.56
US$58.58
+120.6%
13.6%US$70.00US$48.00US$14.3212

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.